Table 2.
Peri‐ and Intraprocedural Management
| Total | Time Interval Between Index Event and Treatment | ||||
|---|---|---|---|---|---|
| N=4717 | 0 to 2 Days n=550 (11.6%) | 3 to 7 Days n=1579 (33.4%) | 8 to 14 Days n=1244 (26.3%) | 15 to 180 Days n=1344 (28.4%) | |
| Intraprocedural monitoring, n (%) | 1685 (35.7) | 164 (29.8) | 527 (33.4) | 436 (35.0) | 558 (41.5) |
| Electroencephalography | 28 (0.6) | 3 (0.5) | 9 (0.6) | 8 (0.6) | 8 (0.6) |
| Transcranial cerebral oximetry | 1216 (25.8) | 122 (22.2) | 380 (24.1) | 323 (26.0) | 391 (29.1) |
| Somatosensory evoked potentials | 40 (0.8) | 3 (0.5) | 20 (1.3) | 8 (0.6) | 9 (0.7) |
| Other methods | 837 (17.7) | 90 (16.3) | 289 (18.3) | 205 (16.5) | 253 (18.8) |
| Endovascular procedure (n, %) | |||||
| Angioplasty alone | 87 (1.8) | 12 (2.2) | 35 (2.2) | 25 (2.0) | 15 (1.1) |
| Stent placement | 294 (6.2) | 32 (5.8) | 109 (6.9) | 68 (5.5) | 85 (6.3) |
| Angioplasty and stent placement | 4336 (91.9) | 506 (92.0) | 1435 (90.9) | 1151 (92.5) | 1244 (92.6) |
| Protection system use, n (%) | 2282 (48.4) | 248 (45.1) | 706 (44.7) | 619 (49.8) | 709 (52.8) |
| Stent design, n (%) | |||||
| Open cell | 1581 (34.1) | 180 (11.4) | 522 (33.8) | 399 (32.7) | 480 (36.1) |
| Closed cell | 2507 (54.1) | 298 (55.4) | 845 (54.7) | 684 (56.1) | 680 (51.2) |
| Semiclosed cell | 455 (9.8) | 55 (10.2) | 152 (9.8) | 122 (10.0) | 126 (9.5) |
| Others | 87 (1.9) | 5 (0.9) | 25 (1.6) | 14 (1.1) | 43 (3.2) |
| Stent type, n (%) | |||||
| Nitinol | 3254 (70.3) | 390 (72.5) | 1063 (68.8) | 833 (68.3) | 968 (72.8) |
| Stainless steel | 1205 (26.0) | 127 (23.6) | 428 (27.7) | 343 (28.1) | 307 (23.1) |
| Others | 171 (3.7) | 21 (3.9) | 53 (3.4) | 43 (3.5) | 54 (4.1) |
| Duration of procedure, min, median (Q1‐Q3) | 47 (40‐60) | 50 (40‐60) | 50 (40‐60) | 45 (40‐60) | 45 (37‐60) |
n, patients with feature or property; N, all patients with information available; Q1‐Q3, interquartile range; min, minutes